Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Combination therapy overcomes immunotherapy resistance in glioblastoma (opens in a new tab)

news-medical.net · 2026-10-08

Short answerEvidenceSource

Short answer

Not supported

Not supported.

2 claims go further than the study. 5 other points were not covered by the paper.

  • 2 overstated
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Two of seven claims overstate the study. Five claims the study doesn't address.

  • 2 overstated
  • 5 not covered
Open claim evidence
3

The source study

Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma

Neuro-Oncology · 2026
Open source record (opens in a new tab)
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma

    Neuro-Oncology · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma

    Publisher (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedScientists at The Wistar Institute identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.View evidenceHide evidence

As statedtwo of the biggest barriers

Why this verdict

The abstract supports a preclinical murine combination strategy targeting hypoxia-driven myeloid immunosuppression and CD137-positive CD8+ T-cell responses, with durable tumor regression and survival outcomes. But the headline’s unhedged claim that the treatment 'overcomes' two of the biggest barriers to glioblastoma immunotherapy is stronger than the abstract-level evidence, which is animal/preclinical and does not establish clinical overcoming of GBM immunotherapy resistance. The headline outruns the story’s own caveat that the evidence is preclinical.

1

Study evidence

Monocyte-derived macrophages (MDMs) and neutrophils are the most abundant intratumoral myeloid subsets and exhibit functionally immunosuppressive states in the SB28 orthotopic GBM model.

“We employed single-cell RNA sequencing, immunophenotyping, and functional analyses in an orthotopic murine GBM model (SB28) to investigate how hypoxia shapes the tumor immune microenvironment and limits CD8+ T cell responses.”
2

Study evidence

Low-dose axitinib reduced intratumoral hypoxia in orthotopic murine GBM (reported in abstract).

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
Claim 2 of 7OverstatedThe researchers showed that reprogramming myeloid cells while simultaneously boosting cancer-fighting T cells shrank glioblastoma tumors and prevented them from coming back.View evidenceHide evidence

As statedshrunk the tumors and prevented them from coming back

Why this verdict

The abstract supports that axitinib plus CD137 agonism in murine GBM was accompanied by durable tumor regression, immunological memory, and long-term survival. However, the story’s phrasing that the approach 'prevented them from coming back' is more absolute than the abstract, which does not provide recurrence/rechallenge details or quantify prevention at this depth.

1

Study evidence

Low‑dose axitinib reduced intratumoral hypoxia, altered glucose uptake and histone lactylation in MDMs and neutrophils, impaired their immunosuppressive function, and promoted expansion of intratumoral PD‑1+CD137+ CD8+ T cells.

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
Claim 3 of 7Not coveredIn a preclinical model, hypoxia was identified as a key factor that made tumor myeloid cells immunosuppressive, and low oxygen alone was enough to convert these cells into potent suppressors of T cells.View evidenceHide evidence

Why this verdict

The abstract supports that hypoxia reprogrammed MDMs and neutrophils into immunosuppressive cells limiting CD8+ T-cell expansion. But the specific claim that low oxygen alone was sufficient to convert these cells into potent T-cell suppressors requires experimental detail not present in the abstract-level profile.

1

Study evidence

Monocyte-derived macrophages (MDMs) and neutrophils are the most abundant intratumoral myeloid subsets and exhibit functionally immunosuppressive states in the SB28 orthotopic GBM model.

“We employed single-cell RNA sequencing, immunophenotyping, and functional analyses in an orthotopic murine GBM model (SB28) to investigate how hypoxia shapes the tumor immune microenvironment and limits CD8+ T cell responses.”
Claim 4 of 7Not coveredLow-dose axitinib reduced oxygen starvation inside the tumor, stopped myeloid cells from being reprogrammed to suppress T cells, and increased T-cell entry into the tumor, but axitinib alone only modestly extended median survival from 17 to 19 days.View evidenceHide evidence

As statedfrom 17 to 19 days

Why this verdict

The abstract supports low-dose axitinib reducing intratumoral hypoxia, impairing myeloid immunosuppressive function, and promoting intratumoral PD-1+CD137+ CD8+ T-cell expansion in SB28. But it does not verify the stronger wording that axitinib 'stopped' myeloid reprogramming, that it increased T-cell 'entry' rather than expansion, or the specific axitinib-alone median survival change from 17 to 19 days.

1

Study evidence

Low-dose axitinib reduced intratumoral hypoxia in orthotopic murine GBM (reported in abstract).

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
2

Study evidence

Low‑dose axitinib reduced intratumoral hypoxia, altered glucose uptake and histone lactylation in MDMs and neutrophils, impaired their immunosuppressive function, and promoted expansion of intratumoral PD‑1+CD137+ CD8+ T cells.

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
Claim 5 of 7Not coveredCombining axitinib with a 4-1BB agonist was more powerful than either treatment alone, extending median survival to 42 days in murine models and yielding a 40% long-term survival rate.View evidenceHide evidence

As statedmedian survival to 42 days; 40% long-term survival

Why this verdict

The abstract supports that the axitinib plus CD137 agonist combination produced durable tumor regression, immunological memory, and long-term survival in murine GBM models. It does not provide the stated quantitative survival values, the 42-day median survival, the 40% long-term survival rate, or a detailed comparison against each monotherapy arm.

1

Study evidence

Low‑dose axitinib reduced intratumoral hypoxia, altered glucose uptake and histone lactylation in MDMs and neutrophils, impaired their immunosuppressive function, and promoted expansion of intratumoral PD‑1+CD137+ CD8+ T cells.

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
Claim 6 of 7Not coveredRe-exposure to tumor cells later did not trigger new tumor growth, suggesting the combination induced lasting immune memory.View evidenceHide evidence

Why this verdict

The abstract reports immunological memory with the combination, which is directionally consistent with the story. However, the specific rechallenge claim that later re-exposure to tumor cells did not trigger new tumor growth is not described in the abstract-level profile.

1

Study evidence

Low‑dose axitinib reduced intratumoral hypoxia, altered glucose uptake and histone lactylation in MDMs and neutrophils, impaired their immunosuppressive function, and promoted expansion of intratumoral PD‑1+CD137+ CD8+ T cells.

“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
Claim 7 of 7Not coveredThe senior author said the strategy may next be tested in a clinical trial for glioblastoma patients and could potentially extend to other hypoxic cancers such as pancreatic cancer.View evidenceHide evidence

Why this verdict

The paper profile at abstract depth does not include the senior author’s future clinical-trial plans or speculation about extension to other hypoxic cancers such as pancreatic cancer. Those may be external article/quote material, but they are not verifiable from the supplied abstract-level paper evidence.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Low-dose axitinib is described in the paper as pharmacologic hypoxia modulation that alters myeloid glucose uptake and histone lactylation, impairing immunosuppressive function.

    The story reflects axitinib’s hypoxia/myeloid-targeting role, but it does not reflect the paper’s more specific metabolic and epigenetic mechanism involving glucose uptake and histone lactylation, which is a central mechanistic element in the abstract profile.

    From in_vivo_pharmacologic_mechanistic; in_vivo therapeutic efficacy study (orthotopic murine GBM models)

  • CD137 is reported as largely expressed by effector-like exhausted CD8+ T-cell subsets, and the combination robustly expands this subset.

    The story broadly says the treatment boosts cancer-fighting T cells but does not convey the paper’s more specific EX-eff CD8+ T-cell state or CD137-expression finding.

    From In vivo orthotopic murine GBM models with scRNA-seq and flow cytometry immunophenotyping

  • The abstract reports a human observational correlation: abundance of PD-1+CD137+CD8+ T cells correlated with improved disease-free survival in GBM patients.

    The story presentation does not mention this human correlative survival analysis. This omission also avoids overstating it, but it is a material paper element not reflected in the story.

    From human observational (secondary/clinical cohort correlation)

3 things the story did carry across
  • The paper’s central evidence is preclinical: orthotopic murine glioblastoma models, including SB28 and CT2A for combination-therapy experiments.
  • Hypoxia is reported to reprogram monocyte-derived macrophages and neutrophils into immunosuppressive cells that limit intratumoral CD8+ T-cell expansion.
  • The axitinib plus CD137 agonist combination is reported to expand effector-like exhausted CD8+ T cells and to be accompanied by durable tumor regression, immunological memory, and long-term survival.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalEvaluate therapeutic efficacy of combining low-dose axitinib with CD137 agonism in murine GBM (SB28 and CT2A), including tumor control, memory, and survival.in vivo therapeutic efficacy study (orthotopic murine GBM models)Expand

In plain English

In orthotopic murine GBM models (SB28, CT2A), pharmacologic hypoxia modulation with low‑dose axitinib combined with agonistic CD137 targeting was reported to (a) alter myeloid cell metabolism and histone lactylation, impairing myeloid immunosuppression and promoting intratumoral PD‑1+CD137+ CD8+ T cells (noted specifically in SB28), and (b) robustly expand effector‑like exhausted (EX‑eff) CD8+ T cells with accompanying durable tumor regression, immunological memory, and long‑term survival.

Key findings

  • Low‑dose axitinib reduced intratumoral hypoxia, altered glucose uptake and histone lactylation in MDMs and neutrophils, impaired their immunosuppressive function, and promoted expansion of intratumoral PD‑1+CD137+ CD8+ T cells.
  • Combination of axitinib and agonistic CD137 targeting robustly expanded effector‑like exhausted (EX‑eff) CD8+ T cell subsets.
“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
What this piece can’t prove
  • The abstract notes some findings as model‑specific (e.g., PD‑1+CD137+ CD8+ T‑cell expansion in SB28), while outcomes in the CT2A model are not fully detailed.

3 further details could not be confirmed from the summary.

2in vivo animalDefine how hypoxia shapes the glioblastoma (GBM) tumor immune microenvironment, particularly immunosuppressive myeloid states and impaired CD8+ T-cell responses, in orthotopic murine GBM.in vivo scRNA-seq and immunophenotyping in orthotopic GBMExpand

In plain English

In an orthotopic murine GBM (SB28) model profiled by single-cell RNA-sequencing, immunophenotyping, and functional assays, the authors report that monocyte-derived macrophages (MDMs) and neutrophils are the dominant myeloid populations in the tumor microenvironment and adopt immunosuppressive states under hypoxia; hypoxia-associated changes in these myeloid cells are associated with restricted intratumoral CD8+ T cell expansion.

Key findings

  • Monocyte-derived macrophages (MDMs) and neutrophils are the most abundant intratumoral myeloid subsets and exhibit functionally immunosuppressive states in the SB28 orthotopic GBM model.
  • Tumor hypoxia reprograms MDMs and neutrophils into immunosuppressive cells, which is associated with limited expansion of intratumoral CD8+ T cells.
“We employed single-cell RNA sequencing, immunophenotyping, and functional analyses in an orthotopic murine GBM model (SB28) to investigate how hypoxia shapes the tumor immune microenvironment and limits CD8+ T cell responses.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

3in vivo animalTest whether pharmacologic hypoxia modulation (low-dose axitinib) alters myeloid metabolism/epigenetics (glucose uptake, histone lactylation) and reduces myeloid immunosuppressive function, enabling intratumoral PD-1+CD137+ CD8+ T-cell expansion (noted as SB28-specific in the abstract).in vivo pharmacologic mechanisticExpand

In plain English

In orthotopic murine GBM models (SB28, CT2A), the authors report that pharmacologic hypoxia modulation with low-dose axitinib reduced intratumoral hypoxia and was associated with altered glucose uptake and histone lactylation in monocyte-derived macrophages (MDMs) and neutrophils. These myeloid metabolic/epigenetic changes were reported to impair myeloid immunosuppressive function and to promote intratumoral expansion of PD-1+CD137+ CD8+ T cells; the CD8+ T cell expansion was noted as specific to the SB28 model in the abstract.

Key findings

  • Low-dose axitinib reduced intratumoral hypoxia in orthotopic murine GBM (reported in abstract).
  • Axitinib treatment was associated with altered glucose uptake and altered histone lactylation in monocyte-derived macrophages and neutrophils.
“Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).”
What this piece can’t prove
  • Reported expansion of PD-1+CD137+ CD8+ T cells is noted as specific to the SB28 model; generalizability across GBM models (e.g., CT2A) and to human GBM requires full-data examination.

4 further details could not be confirmed from the summary.

4in vivo animalIdentify CD137 expression as enriched on effector-like exhausted CD8+ T cells (EX-eff) in GBM models and show that combination therapy expands this subset.In vivo orthotopic murine GBM models with scRNA-seq and flow cytometry immunophenotypingExpand

In plain English

In orthotopic murine GBM models, the study reports that CD137 is predominantly expressed by an effector-like exhausted CD8+ T cell subset (EX-eff). Pharmacologic hypoxia modulation with low-dose axitinib altered myeloid cell metabolism and promoted intratumoral PD-1+CD137+ CD8+ T cells (noted specifically in the SB28 model), and when combined with agonistic CD137 therapy the authors observed a robust expansion of EX-eff CD8+ T cells accompanied by durable tumor regression, immunological memory, and long-term survival.

Key findings

  • CD137 is largely expressed by effector-like exhausted CD8+ T cell subsets (EX-eff) identified in the murine GBM tumor microenvironment.
  • Combination therapy (low-dose axitinib to modulate hypoxia + agonistic CD137 targeting) robustly expanded EX-eff CD8+ T cells and was accompanied by durable tumor regression, immunological memory, and long-term survival in the reported experiments.
“CD137 is largely expressed by effector-like exhausted CD8+ T cell subsets (EX-eff).”
What this piece can’t prove
  • Unclear whether reported CD137 expression enrichment and combination-driven expansion were consistently observed across both GBM models mentioned (SB28 versus CT2A).

4 further details could not be confirmed from the summary.

5secondary dataAssess whether PD-1+CD137+CD8+ T-cell abundance correlates with improved disease-free survival in human GBM patients.human observational (secondary/clinical cohort correlation)Expand

In plain English

The abstract reports that, in human glioblastoma patients, greater intratumoral abundance of PD-1+CD137+CD8+ T cells was associated with improved disease-free survival.

Key findings

  • Abundance of intratumoral PD-1+CD137+CD8+ T cells correlated with improved disease-free survival in patients with glioblastoma as reported in the abstract.
“Additionally, the abundance of PD-1+CD137+CD8+ T cells correlated with improved disease-free survival in patients with GBM.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma

Neuro-Oncology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 41 candidate papers

Selected

Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma

Neuro-Oncology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Corrigendum to: Understanding the effect of categorization of a continuous predictor with application to neuro-oncology

Neuro-Oncology Practice · 2026 · Crossref

Source (opens in a new tab)
Candidate

From discovery to delivery: How can we improve pediatric neuro-oncology clinical trials?

Neuro-Oncology Practice · 2026 · Crossref

Source (opens in a new tab)
Candidate

15 Promoting the need for a dedicated Neuro‑Oncology Occupational Therapy Service at QEHB: A Quality Improvement Project

Neuro-Oncology · 2026 · Crossref

Source (opens in a new tab)

And 35 more candidates considered.